
Alligator Bioscience AB
STO:ATORX

Net Margin
Alligator Bioscience AB
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | Company | Market Cap |
Net Margin |
||
---|---|---|---|---|---|
SE |
![]() |
Alligator Bioscience AB
STO:ATORX
|
173.9m SEK |
-353%
|
|
FR |
![]() |
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
US |
![]() |
Abbvie Inc
NYSE:ABBV
|
333B USD |
7%
|
|
US |
![]() |
Amgen Inc
NASDAQ:AMGN
|
152B USD |
17%
|
|
US |
![]() |
Gilead Sciences Inc
NASDAQ:GILD
|
133.1B USD |
21%
|
|
US |
![]() |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.1B USD |
-9%
|
|
US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
AU |
![]() |
CSL Ltd
ASX:CSL
|
116.2B AUD |
18%
|
|
US |
![]() |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
56.2B USD |
32%
|
|
US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-33%
|
|
US |
![]() |
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
41.7B USD |
-11%
|
Alligator Bioscience AB
Glance View
Alligator Bioscience AB is a biotech company, which engages in the development of innovative antibody-based medicines for immunotherapy of cancer. The company is headquartered in Lund, Skane and currently employs 46 full-time employees. The company went IPO on 2016-11-23. The firm specializes in the development of tumor-targeted immunotherapies, in particular agonist mono- and bispecific antibodies, and is active in the early stages of drug development, from concept to phase II clinical trials. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its technology platform, Neo-X-Prime, with MacroGenics Inc. and drug candidates based on the RUBY bispecific platform with Orion Corporation. Its licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. The firm operates domestically.

See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Alligator Bioscience AB's most recent financial statements, the company has Net Margin of -353.4%.